161 related articles for article (PubMed ID: 24962280)
1. Design of anticancer lysophosphatidic acid agonists and antagonists.
Parrill AL
Future Med Chem; 2014 May; 6(8):871-83. PubMed ID: 24962280
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development.
Meduri B; Pujar GV; Durai Ananda Kumar T; Akshatha HS; Sethu AK; Singh M; Kanagarla A; Mathew B
Eur J Med Chem; 2021 Oct; 222():113574. PubMed ID: 34126459
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease.
Zhou Y; Little PJ; Ta HT; Xu S; Kamato D
Pharmacol Ther; 2019 Dec; 204():107404. PubMed ID: 31472182
[TBL] [Abstract][Full Text] [Related]
4. LPA and its analogs-attractive tools for elucidation of LPA biology and drug development.
Kano K; Arima N; Ohgami M; Aoki J
Curr Med Chem; 2008; 15(21):2122-31. PubMed ID: 18781939
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acid receptor agonists and antagonists (WO2010051053).
Parrill AL
Expert Opin Ther Pat; 2011 Feb; 21(2):281-6. PubMed ID: 21222547
[TBL] [Abstract][Full Text] [Related]
6. Alkyl lysophosphatidic acid and fluoromethylene phosphonate analogs as metabolically-stabilized agonists for LPA receptors.
Xu Y; Tanaka M; Arai H; Aoki J; Prestwich GD
Bioorg Med Chem Lett; 2004 Nov; 14(21):5323-8. PubMed ID: 15454220
[TBL] [Abstract][Full Text] [Related]
7. Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists.
Jiang G; Inoue A; Aoki J; Prestwich GD
Bioorg Med Chem Lett; 2013 Mar; 23(6):1865-9. PubMed ID: 23395664
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid (LPA) receptor-mediated signaling and cellular responses to anticancer drugs and radiation of cancer cells.
Ikeda H; Takai M; Tsujiuchi T
Adv Biol Regul; 2024 May; 92():101029. PubMed ID: 38377635
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi- and Rho-dependent pathways.
Hurst JH; Hooks SB
Pharmacology; 2009; 83(6):333-47. PubMed ID: 19420982
[TBL] [Abstract][Full Text] [Related]
10. Diverse effects of LPA receptors on cell motile activities of cancer cells.
Tsujiuchi T; Hirane M; Dong Y; Fukushima N
J Recept Signal Transduct Res; 2014 Jun; 34(3):149-53. PubMed ID: 24460191
[TBL] [Abstract][Full Text] [Related]
11. LPA(3), a unique G protein-coupled receptor for lysophosphatidic acid.
Hama K; Aoki J
Prog Lipid Res; 2010 Oct; 49(4):335-42. PubMed ID: 20230855
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic acid (LPA) and its receptors.
Noguchi K; Herr D; Mutoh T; Chun J
Curr Opin Pharmacol; 2009 Feb; 9(1):15-23. PubMed ID: 19119080
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.
Lin YH; Lin YC; Chen CC
Cells; 2021 Jun; 10(7):. PubMed ID: 34209775
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid receptors in cancer pathobiology.
Tsujiuchi T; Araki M; Hirane M; Dong Y; Fukushima N
Histol Histopathol; 2014 Mar; 29(3):313-21. PubMed ID: 24194373
[TBL] [Abstract][Full Text] [Related]
15. Unmasking of LPA1 receptor-mediated migration response to lysophosphatidic acid by interleukin-1β-induced attenuation of Rho signaling pathways in rat astrocytes.
Sato K; Horiuchi Y; Jin Y; Malchinkhuu E; Komachi M; Kondo T; Okajima F
J Neurochem; 2011 Apr; 117(1):164-74. PubMed ID: 21244430
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid and its receptor LPA
Srikanth M; Chew WS; Hind T; Lim SM; Hay NWJ; Lee JHM; Rivera R; Chun J; Ong WY; Herr DR
Eur J Pharmacol; 2018 Dec; 841():49-56. PubMed ID: 30321532
[TBL] [Abstract][Full Text] [Related]
17. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
Komachi M; Tomura H; Malchinkhuu E; Tobo M; Mogi C; Yamada T; Kimura T; Kuwabara A; Ohta H; Im DS; Kurose H; Takeyoshi I; Sato K; Okajima F
Carcinogenesis; 2009 Mar; 30(3):457-65. PubMed ID: 19129242
[TBL] [Abstract][Full Text] [Related]
18. The development of modulators for lysophosphatidic acid receptors: A comprehensive review.
Liu W; Hopkins AM; Hou J
Bioorg Chem; 2021 Dec; 117():105386. PubMed ID: 34695732
[TBL] [Abstract][Full Text] [Related]
19. Roles of LPA receptor signaling in breast cancer.
Wang J; Sun Y; Qu J; Yan Y; Yang Y; Cai H
Expert Rev Mol Diagn; 2016 Oct; 16(10):1103-1111. PubMed ID: 27644846
[TBL] [Abstract][Full Text] [Related]
20. Endogenous lysophosphatidic acid (LPA
Sattikar A; Dowling MR; Rosethorne EM
Br J Pharmacol; 2017 Feb; 174(3):227-237. PubMed ID: 27864940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
